Detecting biomarkers associated with antipsychotic-induced extrapyramidal syndromes by using machine learning techniques

被引:2
|
作者
Kalelioglu, Tevfik [1 ]
Karamustafalioglu, Nesrin [2 ]
Emul, Murat
Celikel, Guler [2 ]
Ozonder, Ipek [2 ]
Kara, Aysu [2 ]
Kilic, Cenk [2 ]
Yalcin, Suat [2 ]
Celik, Ecem [2 ]
Kilic, Ugur [3 ]
Ladoni, Ahoora [1 ]
Ragone, Emma [1 ]
Centeno, Caroline [1 ]
Penberthy, J. Kim [1 ]
机构
[1] Univ Virginia, Dept Psychiat & Neurobehav Sci, Sch Med, Charlottesville, VA 22903 USA
[2] Bakirkoy Mental Hlth Res & Training State Hosp, Dept Psychiat, Istanbul, Turkiye
[3] Univ Virginia, Dept Engn Syst & Environm, Charlottesville, VA USA
关键词
Extrapyramidal syndrome; Biomarkers; Machine learning; SYMPTOMS; HALOPERIDOL;
D O I
10.1016/j.jpsychires.2023.01.003
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: Antipsychotic-associated extrapyramidal syndromes (EPS) are a common side effect that may result in discontinuation of treatment. Although some clinical features of individuals who develop specific EPSs are well defined, no specific laboratory parameter has been identified to predict the risk of developing EPS. Methods: Three hundred and ninety hospitalizations of patients under antipsychotic medication were evaluated. Machine learning techniques were applied to laboratory parameters routinely collected at admission.Results: Random forests classifier gave the most promising results to show the importance of parameters in developing EPS. Albumin has the maximum importance in the model with 4.28% followed by folate with 4.09%. The mean albumin levels of EPS and non-EPS group was 4,06 +/- 0,40 and 4,24 +/- 0,37 (p = 0,027) and folate level was 6,42 +/- 3,44 and 7,95 +/- 4,16 (p = 0,05) respectively. Both parameters showed lower levels in EPS group.Conclusions: Our results suggest that relatively low albumin and folate levels may be associated with developing EPS. Further research is needed to determine cut-off levels for these candidate markers to predict EPS.
引用
收藏
页码:300 / 304
页数:5
相关论文
共 50 条
  • [1] Management of acute antipsychotic-induced extrapyramidal syndromes
    Remington, G
    BezchlibnykButler, K
    [J]. CNS DRUGS, 1996, 5 : 21 - 35
  • [2] Myasthenic Crisis May Mimic Antipsychotic-Induced Extrapyramidal Syndromes
    Chiu, Yu-Hui
    Yang, Albert C.
    Chern, Chii-Hwa
    How, Chorng-Kuang
    [J]. JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES, 2011, 23 (02) : E36 - E37
  • [3] Antipsychotic-induced extrapyramidal symptoms and their management
    Dayalu, Praveen
    Chou, Kelvin L.
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (09) : 1451 - 1462
  • [4] Pharmacogenetics of antipsychotic-induced extrapyramidal symptoms
    Lerer, B.
    Greenbaum, L.
    Alkelai, A.
    Lifschytz, T.
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2010, 13 : 22 - 23
  • [5] Antipsychotic-induced extrapyramidal syndromes in psychiatric practice: A case-control study
    Schillevoort, I
    Herings, RMC
    Hugenholtz, GWK
    de Boer, A
    Nolen, WA
    Roos, RAC
    Leufkens, HGM
    [J]. PHARMACY WORLD & SCIENCE, 2005, 27 (04): : 285 - 289
  • [6] Antipsychotic-induced Extrapyramidal Syndromes in Psychiatric Practice: A Case-control Study
    I. Schillevoort
    R. M. C. Herings
    A. de. Boer
    H. G. M. Leufkens
    G. W. K. Hugenholtz
    W. A. Nolen
    R. A. C. Roos
    [J]. Pharmacy World and Science, 2005, 27 : 285 - 289
  • [7] Antipsychotic-induced tardive syndromes
    Fleischhacker W.W.
    Hofer A.
    Jagsch C.
    Pirker W.
    Psota G.
    Rittmannsberger H.
    Seppi K.
    [J]. neuropsychiatrie, 2016, 30 (3) : 123 - 130
  • [8] Antipsychotic-induced extrapyramidal syndromes - Risperidone compared with low- and high-potency conventional antipsychotic drugs
    Schillevoort, I
    de Boer, A
    Herings, RMC
    Roos, RAC
    Jansen, PAF
    Leufkens, HGM
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 57 (04) : 327 - 331
  • [9] Serotonergic regulation of antipsychotic-induced extrapyramidal side effects
    Imaki, Junta
    Tatara, Ayaka
    Imaoku, Takuji
    Okano, Motoki
    Ohno, Yukihiro
    [J]. JOURNAL OF PHARMACOLOGICAL SCIENCES, 2010, 112 : 185P - 185P
  • [10] Switching to quetiapine in schizophrenic patients with antipsychotic-induced extrapyramidal symptoms
    Bovio, H
    Jimenez, J
    Herranz, S
    Estiarte, R
    Ovejero, C
    Perez, A
    Riso-Villademoros, F
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2002, 12 : S267 - S267